Condylomata Acuminata Clinical Trial
Official title:
An Investigational Vaccine in Reducing the Incidence of Anogenital Warts in Young Men
This study was conducted to demonstrate that Gardasil™ (quadrivalent human papillomavirus [qHPV] vaccine) 1) is well tolerated in young men, 2) reduces incidence of external genital lesions in young men, 3) reduces the incidence of anal intraepithelial neoplasia (AIN) or anal cancer in men having sex with men (MSM), and 4) reduces incidence of Human Papillomavirus (HPV) infection in young men. In the 7-month Base Study participants received randomly assigned qHPV vaccine or placebo at Day 1, Month 2, and Month 6. Base Study follow-up continued through Month 36. In Extension 1 (EXT1), participants who received placebo or an incomplete qHPV vaccine regimen in the Base Study were offered qHPV vaccine. Participants were followed in EXT1 for 7 months. In Extension 2 [LTFU (EXT2)], long-term effectiveness, immunogenicity, and safety of qHPV vaccine were followed up to 10 years following study enrollment. Participants who received ≥1 dose of qHPV vaccine in the Base Study or EXT1 were eligible to enroll in LTFU (EXT2).
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04537156 -
Efficacy, Immunogenicity and Safty Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 3 | |
Completed |
NCT00973856 -
Evaluation of the Effectiveness of an Alcohol Based Hand Gel for the Reduction of Warts on the Hands
|
N/A | |
Completed |
NCT02015260 -
A Trial of the Efficacy and Safety of Topical Nitric Oxide in Patients With Anogenital Warts
|
Phase 2 | |
Active, not recruiting |
NCT05056402 -
An Immuno-bridging Study of a Nonavalent HPV Vaccine (E.Coli) in Healthy Population Aged 9-17 vs Aged 18-26 Years Old
|
Phase 3 | |
Withdrawn |
NCT00365443 -
Broad Spectrum HPV Vaccine Tolerability, Immunogenicity, and Efficacy Study (V502-003)
|
Phase 2 | |
Not yet recruiting |
NCT01483794 -
Epidemiology, Costs and Psychosocial Consequences of Genital Warts in Valparaiso, Chile
|
N/A | |
Completed |
NCT03935204 -
Immunogenicity Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 2 | |
Completed |
NCT02405520 -
Safety and Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
|
Phase 1 | |
Active, not recruiting |
NCT02710851 -
Immunogenicity Study of the Recombinant Human Papillomavirus Virus Type 6/11 Bivalent Vaccine
|
Phase 2 | |
Completed |
NCT04782895 -
Immunogenicity of a Recombinant Human Papillomavirus Nonavalent (Types 6,11,16,18,31,33,45,52,58)Vaccine(E.Coli) Versus Gardasil®9 in Healthy Females 18-26 Years of Age
|
Phase 3 | |
Completed |
NCT03546842 -
Safety and Immunogenicity Study of V503 (GARDASIL™9, 9vHPV Vaccine) Administered to 9- to 26-Year-Old Females and Males in Vietnam (V503-017)
|
Phase 3 | |
Completed |
NCT03981822 -
A Placebo-Controlled Study Using VP-102 in the Treatment of External Genital Warts
|
Phase 2 | |
Recruiting |
NCT03158480 -
Safety and Efficacy of Immune Therapy for Condyloma
|
N/A | |
Completed |
NCT01598779 -
Human Papillomavirus (HPV) Types Present in External Genital Warts (EGW) in the Argentinean Population
|
N/A | |
Not yet recruiting |
NCT06430190 -
Peginterferon α-2b Combined CO2 Laser in Condylomata Acuminata
|
N/A | |
Completed |
NCT00449982 -
Efficacy and Safety Study of Polyphenon E to Treat External Genital Warts
|
Phase 3 | |
Completed |
NCT03813940 -
Safety Study of Recombinant Human Papillomavirus Vaccine(6,11,16,18,31,33,45,52,58 Type)(E.Coli)
|
Phase 1 | |
Not yet recruiting |
NCT06197802 -
Plateau Antibody Levels of a Recombinant (E.Coli) HPV Nonavalent Vaccine Versus Gardasil®9 in Young Women
|
||
Completed |
NCT01532102 -
Safety and Efficacy Study of Topical AP611074 Gel to Treat Genital Warts
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT06297187 -
Cavitronic Ultrasonic Surgical Aspiration (CUSA) Women's Health Study
|